l General Information |
Product Name | Strontium Ranelate |
General description | Strontium ranelate is a medication for osteoporosis. Studies indicate it can also slow the course of osteoarthritis of the knee. |
Synonym | distrontium;5-[bis(carboxylatomethyl)amino]-3-(carboxylatomethyl)-4-cyanothiophene-2-carboxylate; Protelos; Protos; Distrontium renelate; Osseor |
Purity | ≥99%(HPLC) | CAS Number | 135459-87-9 |
Formula | C12H6N2O8SSr2 | Molecular Weight | 513.486 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White to Off-white solid |
Solubility(25℃) | DMSO | Insoluble |
Ethanol | Insoluble |
Water | Insoluble |
l Biological Information |
Biochem/Physiol Actions | In general, it is believed that strontium ranelate is capable of affecting a rebalance in bone turnover in favour of bone formation by: (1) increasing osteoblast differentiation from progenitors, osteoblast activity and survival, as well as regulating osteoblast-induced osteoclastogenesis, and (2) decreasing osteoclast differentiation and activity, as well as increasing osteoclast apoptosis [A31541]. It has also been shown that strontium ranelate is capable of improving and strengthening various components of overall bone tissue quality like bone mineral density and bone microarchitecture [A31541, A31542, A31553]. |
Application | Bone Density Conservation Agents |
l Packaging & Storage |
Packaging | 250mg; 1g |
Storage temp. | 0-5℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
